Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP-938 multiple-dose RSV challenge study
2018-001878-21Phase 2Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in respiratory syncytial virus disease (RSV) comparing EDP-938 with Placebo (2 arms). Primary endpoint: RSV viral load AUC by RT-qPCR. Started Jul 2018; status: completed.
02
Drugs
zelicapavir
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2018-001878-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001878-21.